98%
921
2 minutes
20
Intestinal carriage of extended-spectrum β-lactamase-producing (ESBL-PE carriage) poses a health risk to the elderly. It was aimed to study the prevalence and the risk factors of intestinal ESBL-PE carriage in the elderly. An observational study of a 921-elderly cohort was examined at health checkup for intestinal ESBL-PE carriage at a tertiary medical center in Shanghai. The prevalence and risk factors of intestinal ESBL-PE carriage, especially antimicrobial use in the preceding 9 months, were studied. The prevalence of intestinal ESBL-PE carriage was 53.3% (491/921) in community-dwelling elderly people. A total of 542 ESBL-producing isolates, including ( = 484) and ( = 58), were obtained. On genotyping, the CTX-M-9 ESBL was the most prevalent for 66.0% (358/542) of all isolates. Multivariate analysis showed that antibiotic exposure, age (61-70 years), and nursing home residence were independent risk factors of the ESBL-PE carriage. The analysis on the monthly use of antimicrobials showed that antibiotic exposure during the 6 months prior to sample collection contributed to the high prevalence of ESBL-PE carriage. A single exposure to an antimicrobial increased the risk of the carriage significantly, and the risk increased with the frequency of antimicrobial exposure (RR, 1.825 to 5.255). Prior use of second or third generation cephalosporins, fluoroquinolones, and macrolides increased the risk of the carriage. The results of this study indicate the importance of using antimicrobials judiciously in clinical settings to reduce antimicrobial resistance. Further studies with multiple center surveillance and with comparison of ESBL-PE carriage in the elderly and in the general population simultaneously are needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312271 | PMC |
http://dx.doi.org/10.3390/antibiotics11070953 | DOI Listing |
Enferm Infecc Microbiol Clin (Engl Ed)
June 2025
Hospital del Mar, Barcelona, Spain; Hospital del Mar Research Institute (IMIM), Barcelona, Spain; Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra (UPF), Barcelona, Spain; Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos
Objectives: To determine the prevalence of and risk factors for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) faecal carriage among healthy volunteers from Barcelona, and to estimate the pooled prevalence in the community in Spain.
Methods: University students were asked to complete a questionnaire and provide a rectal swab, which was tested for ESBL-producing, ciprofloxacin- and trimethoprim-sulfamethoxazole-resistant Enterobacterales. Risk factors for carriage of antimicrobial resistance were identified by multivariate logistic regression.
BMC Infect Dis
January 2025
Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Ouagdougou, 11 BP218, Burkina Faso.
Background: Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE), particularly Escherichia coli and Klebsiella pneumoniae, have been consistently associated with treatment failure, high mortality and morbidity. The emergence of carbapenem resistance among ESBL-PE strains exacerbates the antimicrobial resistance. However, data are very limited in developing countries as Burkina Faso.
View Article and Find Full Text PDFFront Microbiol
January 2025
Medical Research Center, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Introduction: The global rise of extended-spectrum beta-lactamase-producing (ESBL-PE) challenges resource-limited countries with insufficient laboratory infrastructure. This study investigates fecal carriage and risk factors for ESBL-PE and carbapenemase-producing organisms among patients with urinary tract infection (UTI) in rural Tanzania.
Methods: This cross-sectional study was conducted at St.
J Hosp Infect
March 2025
Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Infectious Diseases, Department of Diagnostic and Public Health, University Hospital Verona, Verona, Italy; DZIF-Clinical Research Unit, Infectious Diseases, Department of Internal Medicine I,
BMC Microbiol
November 2024
School of Medical Laboratory Sciences, Institute of Health Sciences, Jimma University, Jimma, Ethiopia.